🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Characterization of Circulating and Tumor-infiltrating Immune Cells in Malignant Brain Tumors

Recruitingn/aAges 18 Years - anyAllPietro Mortini, MD, Prof.
NCT05831631 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to characterize the circulating leukocyte profile and the immune T cells distribution within the tumor in patients with malignant brain tumors and to correlate these findings with the oncological outcome. Participants will be subjected to blood sampling before surgery and for 12 months of follow-up. Additional sampling and analysis will be performed on tumor samples.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion criteria: * Adult patients (≥18 years) * Able to express informed consent * With primary or secondary malignant brain tumor * Requiring neurosurgical treatment (radiosurgery, stereotactic biopsy, surgery) Exclusion Criteria: * Patients who do not meet inclusion criteria.
💊

What it tests

  • Circulating leukocytes immunophenotype
  • Tumor sampling
📍

Where

1 site
IRCCS San Raffaele Scientific Institute
Milan, Italy
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy